Alogliptin: a review of its use in patients with type 2 diabetes mellitus.

Abstract

The dipeptidyl peptidase-4 inhibitor alogliptin (Nesina®, Vipidia®) is approved in numerous countries worldwide for the treatment of type 2 diabetes mellitus. Fixed-dose combinations of alogliptin/metformin (Kazano®, Vipdomet®) and alogliptin/pioglitazone (Oseni®, Incresync®) are also available. This article reviews the clinical efficacy and tolerability of oral alogliptin in the treatment of type 2 diabetes. Results of randomized controlled trials demonstrated that oral alogliptin improved glycaemic control when administered as monotherapy, as dual therapy in combination with metformin, pioglitazone, a sulfonylurea, voglibose or insulin, or as triple therapy in combination with metformin plus pioglitazone. Alogliptin was generally well tolerated in patients with type 2 diabetes and was weight neutral, with a low risk of hypoglycaemia. Results of the large, well designed EXAMINE trial revealed that alogliptin was not associated with an increased risk of major cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome. In conclusion, alogliptin is a useful option for the treatment of patients with type 2 diabetes.

• Authors: Gillian M Keating
• Journal: Drugs (Drugs) Vol. 75 Issue 7 Pg. 777-96 (May 2015) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 25855222 (Publication Type: Journal Article, Review)

Chemical References

• Hypoglycemic Agents
• Piperidines
• Uracil
• alogliptin

Topics

• Animals
• Diabetes Mellitus, Type 2 (drug therapy)
• Drug Therapy, Combination (methods)
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Piperidines (adverse effects, pharmacology, therapeutic use)
• Randomized Controlled Trials as Topic
• Uracil (adverse effects, analogs & derivatives, pharmacology, therapeutic use)